Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 5, 1998, Pages 723-739

  Chang, Wen Ho ^a   Lin, Shih Ku ^a   Lane, Hsien Yuan ^a   Wei, Fu Chuan ^b   Hu, Wei Herng ^a   Lam, Y W Francis ^c   Jann, Michael W ^d  

^a TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^b Hung Chi Psychiatric Hospital   (Taiwan)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d MERCER UNIVERSITY   (United States)

Author keywords

Clozapine; Clozapine N oxide concentrations; Reversible metabolism

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CROSS-OVER STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032127071     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00035-9     Document Type: Article

References (32)

1. BALDESSARINI, R.J., CENTERRINO, F.C., FLOOD, J.G., VOLPICELLI, S.A., HUSTON-LYONS, D., and COHEN, B.M. (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacol, 9: 117-124.
2. BERTILSSON, L., CARRILLO, J.A., DAHL, M.L., LLERENA, A., ALM, C., BONDESSON, U ., LINDSTROM, L., DELARUBIA, I., RAMOS, S., and BENITEZ, J. (1994) Clozapine disposition covaries with CYP 1A2 activity determined by caffeine test. Br J Clin Pharmacol, 38: 471-473.
3. BONDESSON, U. and LINDSTROM, L.H. (1988) Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacol, 95: 472-475.
4. CENTORRINO, F., BALDESSARNI, R.J., KANDO, J., FRANDENBURG, F.R., VOLPICELLI, S.A., PUOPOLO, P.R., and FLOOD, J.G. (1994) Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiat, 151: 123-125.
5. CENTORRINO, F., BALDESSARINI, R.J., FRANKENBURG, F.R., KANDO, J., VOLPICELLI, S.A., and FLOOD, J.G. (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiat, 153: 820-822.
6. CHONG, S.A., TAN, C.H., KHOO, Y.M., LEE, H.S., WONG, K.E., NGUI, F., and WINSLOW, M. (1997) Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Therapeutic Drug Monitor, 19: 219-223.
7. CHUNG, M.C., LIN, S.K., CHANG, W.H., and JANN, M.W. (1993) Determination of clozapine and desmethylclozapine in human using plasma by high-performance liquid chromatography with ultraviolet detection. J Chromat Biomed Appl, 613: 168-173.
8. EBLING, W.F. and JUSKO, W.J. (1986) The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: The reversible metabolism of methylprednisolone and methylprednisone in rats. J Pharmacokinet Biopharm, 14: 567-599.
9. FANG, J., BAKER, G.B., COUTTS, R.T., and MCKENNA, K.F. (1996) Elucidation of individual cytochrome P450 isoenzymes involved in the metabolism of clozapine. 7th North American ISSX Mtg, San Diego, CA, 10: 356.
10. FISCHER, V., VOGELS, B., MAURER, G., and TYNES, R.E. (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther, 260: 1355-1360.
11. FORSMAN, A. and OHMAN, R. (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res, 21: 396-410.
12. HARING, C., MEISE, W., HUMPEL, C., SARIA, A., FLEISCHHACKER, W., and HINTERHUBER, H. (1989) Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age. Psychopharmacol, 99: S38-S40.
13. HARlNG, C., FLEISCHHACKER, W., SCHETT, P., HUMPEL, C., BARNAS, C., and SARIA, A. (1990) Influence of patient-related variables on clozapine plasma levels. Am J Psychiat, 147: 1471-1475.
14. JANN, M.W., LAN, Y.W.F., and CHANG, W.H. (1990) Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacol, 101: 107-111.
15. JANN, M.W. (1991) Clozapine. Pharmacotherapy, 11: 179-195.
16. JANN, M.W., GRIMSLEY, S.R., GRAY, E.C., and CHANG, W.H. (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet, 24: 161-176.
17. JANN, M.W., LAM, Y.W.F., and CHANG, W.H. (1994) Rapid formation of clozapine in guinea pigs and man following clozapine N-oxide administration. Arch Inter Pharmacodyn Ther, 328: 243-250.
18. JERLING, M., LINDSTROM, L., BONDESSON, U., and BERTISSON, L. (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monitor, 16: 368-374.
19. KOPONEN, H.J., LEINONEN, E., and LEPOLA, U. (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur J Neuropsychopharmacol, 6: 69-71.
20. KORPI, E.R., COSTAKOS, D.T., and WYATT, R.J. (1985) Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol, 34: 2923-2937.
21. KRONIG, M.H., MUNNE, R.A., SZYMANSKI, S., SAFFERMAN, A.Z., POLLACK, S., COOPER, T., KANE, J.M., and LIEBERMAN, J.A. (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiat, 152(2): 179-182.
22. LIN, S.K., CHANG, W.H., CHUNG, M.C., LAM, Y.M.F., and JANN, M.W. (1994) Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol, 34: 318-324.
23. LIU, H.C., CHANG, W.H., WEI, F.C., LIN, S.K., and JANN, M.W. (1996) Monitoring of plasm clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monitor, 18: 200-207.
24. MATSUDA, K.T., CHO, M.C., LIN, K.M., SMITH, M.W., YOUNG, A.S., and ADAMS, J.A. (1996) Clozapine dosage, serum-levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bulletin, 32(2): 253-257.
25. MlDHA, K.K., HAWES, E.H., HUBBARD, J.H., KORCHINSKI, E.D., and MCKAY, G. (1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacol, 96: 206-211.
26. MILLER, D.D., FLEMING, F., HOLMAN, T.L., and PENNY, P.J. (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psych, 55(suppl B): 117-121.
27. OYEWUMI, L.K., FREEMAN, D.J., and VOLLICK, D. (1995) Can low-dose clozapine pharmacokinetics predict steady-state plasma concentrations? Ther Drug Monitor, 17: 137-141.
28. PERRY, P.J., MILLER, D.D., ARNDT, S.V., and CADORET, R.J. (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiat, 148: 231-235.
29. POTKIN, S.G., BERA, R., GULASEKARAM, B., COSTA J., HAYES, S., JIN, Y., RICHMOND, G., C ARREON, D., SITANGGAN, K., GERBER, B., TELFORD, J., PLON, L., PLON, H., PARK, L., CHANG, Y.J., OLDROYD, J., and COOPER, T.B. (1994) Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiat, 55 (9, suppt B): 133-136.
30. SCHMUTZ, J. (1980) Some reflections on molecular structure and biological activity of tricyclic neuroleptics. In. Phenothiazines and structurally related drugs. Usdin et al (Eds.). Vol. 7, p. 3-11. Elsevier, New York.
31. WAGSTAFF, A.J. and BRYSON, H.M. (1995) Clozapine. CNS Drugs, 4: 370-400.
32. WEIGMANN, H. and HIEMKE, C. (1992) Determination of clozapine and its major metabolites in human serum using automated solid phase extraction and subsequent isocratic high performance liquid chromatography. J Chromat Biomed Appl, 583: 209-216.